Dyne Therapeutics, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. Dyne is a clinical-stage biotechnology company developing muscle-disease therapeutics using its FORCE platform. It had no product revenue and reported operating losses.
Financial performance and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $34.7m | $36.5m | $109.6m | $79.0m |
| General and administrative expense | $7.6m | $6.3m | $21.2m | $19.1m |
| Total operating expenses | $42.3m | $42.8m | $130.8m | $98.1m |
| Net loss | $41.4m | $42.6m | $129.3m | $97.5m |
| Net loss per share | $0.80 | $0.83 | $2.50 | $1.92 |
| Operating cash used | Not separately stated | Not separately stated | $124.5m | $91.5m |
- At September 30, cash and cash equivalents were $144.9m and marketable securities were $103.2m, totaling $248.1m. Current assets were $258.2m and current liabilities $23.3m.
- Total liabilities were $49.9m, including $31.2m of lease liabilities. The balance sheet shows no separate borrowings or debt balance.
- Cash, cash equivalents and restricted cash decreased by $56.3m over the first nine months. Investing activities provided $68.0m, largely from marketable-security maturities; financing provided $0.2m.
- Margins are not meaningful because the company had no revenue. Accumulated deficit was $357.7m.
Changes versus comparable periods
- Q3 operating expenses declined $0.5m and net loss improved $1.2m year over year. Higher DYNE-101 clinical preparation and personnel/facility costs were offset by lower DYNE-251 manufacturing costs versus the prior-year period.
- For the first nine months, operating expenses increased $32.8m and net loss worsened $31.8m year over year, mainly from greater clinical-trial and manufacturing activity for DYNE-101 and DYNE-251, higher R&D headcount, and facility costs.
- Cash used in operations rose $33.0m year over year. The 2021 period included $157.2m of net follow-on offering proceeds; no comparable offering proceeds were received in 2022.
Programs, outlook and key risks
- Dyne initiated the Phase 1/2 ACHIEVE trial of DYNE-101 for myotonic dystrophy type 1 (DM1) and began dosing the Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy (DMD) in Q3. The company anticipated safety and other initial data from both trials in the second half of 2023.
- In September, Dyne prioritized DYNE-101 and DYNE-251 and deferred the planned DYNE-301 FSHD IND submission, originally targeted for the second half of 2022. It planned an FSHD program update in 2023. FDA granted DYNE-251 Fast Track designation in October 2022, after quarter-end; this does not assure faster approval.
- Management estimated existing cash, cash equivalents and marketable securities would fund operations and capital needs through 2024 and support proof-of-concept readouts for DYNE-101 and DYNE-251. The filing cautions that this estimate depends on assumptions and says additional funding will be needed to sustain development.
- Key risks include clinical and regulatory failure or delay, uncertain safety and efficacy of the unproven FORCE approach, competition, reliance on third parties and single-source suppliers for key components, intellectual-property challenges, and the possibility that additional financing is unavailable or dilutive. The company reported no material business disruption from COVID-19 to date but continued to monitor potential effects.
- The company expects significant operating losses and rising expenses for the foreseeable future; profitability and product revenue depend on successful development, approval and commercialization. It reported no material changes to critical accounting policies. Disclosure controls were assessed as effective at a reasonable-assurance level.
Important facts for investors to verify
- Progress, safety, tolerability and data timing for ACHIEVE and DELIVER, including whether initial readouts occur as anticipated.
- Whether the stated cash runway through 2024 remains achievable as trial costs, enrollment and manufacturing needs evolve.
- The timing and implications of the deferred DYNE-301 program update and any change in resource allocation.
- Availability and terms of future financing, including potential dilution; the filing says the company had not made sales under its at-the-market program as of the report.
- Exposure to key suppliers, clinical-trial execution, regulatory requirements and intellectual-property disputes.